Plain-English translation of NCT03614650 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new type of immunotherapy called engineered immune effector (EIE) cells for people with digestive tract cancers like stomach, colon, and esophageal cancer. Researchers take your own immune cells, modify them in the laboratory to better recognize and attack cancer, and then give them back to you through injection. The goal is to see if this treatment is safe and whether it can help shrink your cancer.
Digestive tract cancers are very common and deadly, especially when diagnosed at advanced stages. Most patients still don't survive five years even with standard treatment. This new treatment aims to harness your own immune system in a more powerful way to fight these cancers.
You likely qualify if…
You likely don't qualify if…
If you join this trial, doctors will take a sample of your cancer tissue and a sample of your blood or immune cells. Your cells will be sent to a laboratory where scientists will engineer them to recognize your cancer. While your cells are being prepared—which takes several weeks—you may continue other treatments if needed. Once your engineered cells are ready, you will receive injections of them either through your vein or directly into your tumor. You will then be closely monitored with blood tests and imaging to see how well the treatment works and to watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~100 participants
Started
July 2025
Primary completion
June 2028
Age range
1 Year – 80 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.